We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
There have been very rare reports of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with pseudoephedrine.
Respiratory syncytial virus immunisation information for public health professionals, including updates.
This technical article summarises the findings of the influenza (flu) and respiratory syncytial virus (RSV) pilot survey which was run from October 2022 to March 2023. This pilot survey was run as part of the Coronavirus (COVID-19) Infection Survey (CIS),...
The MHRA has reviewed the latest evidence relating to the very rare risk of PRES and RCVS associated with medicines containing pseudoephedrine
Analysis from a COVID-19 Infection Survey pilot that has been testing for influenza (flu) and respiratory syncytial virus (RSV) since October 2022.
American viticultural area
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).